SAGA lands agreement with Region Örebro University Hospital to deploy ultra sensitive liquid biopsy testing in lung cancer

Press photo from Region Örebro Fribild

LUND, Sweden — /September 9, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered a “lab-in-lab” customer agreement with the University Hospital Örebro (USÖ), Division of Laboratory Medicine, serving the healthcare region of Örebro County.  As part of the deal, SAGA is deploying its proprietary technology within the laboratories of the USÖ, who will then use SAGA’s approach for tissue and liquid biopsy testing in samples from patients with non-small lung cancer (NSCLC).

“For lung cancer patients treated with EGFR TKIs, resistance mutations is a big problem and in order to detect those mutations effectively in both tissue and plasma samples you need an assay with very high sensitivity as well as specificity.  After benchmarking, we determined SAGA’s tests offered the highest sensitivity to identify more samples with mutations.  We’re happy to be entering this partnership.”

Gisela Helenius, Department of Laboratory Medicine, University Hospital Örebro

Lung cancer, with 1.2 million new diagnoses per year worldwide, is in need of improved ultrasensitive diagnostics to monitor patients and identify DNA mutations that can help determine optimal therapy choice. Due to the location of tumors near vital organs, conventional tissue biopsy can be challenging and risky. Moreover, therapy-resistance is common and monitoring for the evolution of mutations during patient follow-up is desirable. For these reasons, an easy blood sample-based genomic test may offer advantages to the patient and caregivers.

“We are pleased to sign our second major hospital system in Sweden, validating the interest in and benefits of SAGA’s technologies.  Örebro is one of the trailblazer hospitals in the Nordics, and we look forward to working with them in lung cancer and other cancer types.”

Åke Nilsson, Director of Corporate and Business Development at SAGA Diagnostics

SAGA’s technology for ultrasensitive detection of circulating tumor DNA (ctDNA) and gene mutations is rapid and cost effective. Within a core laboratory, a test can go from sample to result within the same day. Moreover, SAGA offers industry-leading performance to a lower limit of detection of ~0.001% mutant allele fraction, which is approximately 100-fold improved over competing approaches.

“SAGA’s tests for actionable mutations in genes such as EGFR could have immediate impact to improve patient quality of life and outcomes based on what is already known about these important biomarkers. We offer our tests as both as a service, and also via lab-in-lab partnerships as we have here together with Region Örebro University Hospital.”

SAGA CEO Lao Saal

Contact: CEO Lao Saal, MD PhD   lao.saal@sagadiagnostics.com   Phone: +46 (0)733 – 01 72 42


About SAGA Diagnostics

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.

For more information please contact us, and follow us on Twitter @SAGAdiagnostics and LinkedIn.